Kinetic Hairpin Oligonucleotide Blockers for Selective Amplification of Rare Mutations

Yanwei Jia1,2, J. Aquiles Sanchez1 & Lawrence J. Wangh1

1Department of Biology, Brandeis University, Waltham, MA 02453, USA, 2State Key Laboratory of Analog and Mixed-Signal VLSI, University of Macau, Macau, China.

Detection of rare mutant alleles in an excess of wild type alleles is increasingly important in cancer diagnosis. Several methods for selective amplification of a mutant allele via the polymerase chain reaction (PCR) have been reported, but each of these methods has its own limitations. A common problem is that Taq DNA polymerase errors early during amplification generate false positive mutations which also accumulate exponentially. In this paper, we described a novel method using hairpin oligonucleotide blockers that can selectively inhibit the amplification of wild type DNA during LATE-PCR amplification. LATE-PCR generates double-stranded DNA exponentially followed by linear amplification of single-stranded DNA. The efficiency of the blocker is optimized by adjusting the LATE-PCR temperature cycling profile. We also demonstrate that it is possible to minimize false positive signals caused by Taq DNA polymerase errors by using a mismatched excess primer plus a modified PCR profile to preferentially enrich for mutant target sequences prior to the start of the exponential phase of LATE-PCR amplification. In combination these procedures permit amplification of specific KRAS mutations in the presence of more than 10,000 fold excess of wild type DNA without false positive signals.

Detection of rare mutations associated with biomarkers is important for early detection, diagnosis, enhanced personalized therapy, and accurate prognosis of cancers. Detection of rare mutations is also important for assessment of residual disease after surgery or radio/chemotherapy and for early identification of treatment resistance4–8. For example, sensitive analysis of KRAS mutations in codons 12 and 13, as well as certain EGFR mutations is critical for choosing which drug to prescribe at each stage of the lung disease4–8. Recently, the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network have updated their guidelines with a recommendation that therapies including panitumumab or cetuximab be limited to patients with advanced or metastatic colon or rectal cancers carrying wild-type KRAS4,5,10. In addition, there is increased reliance on detection of rare circulating tumor cells or tumor DNA in blood for identification of very early-stage tumors or for tumors that are difficult or impossible to biopsy1,12.

Real-time polymerase chain reaction (PCR) strategies for detection of minority alleles have been thoroughly reviewed by Milbury et al. These include the use of allele-specific, amplification-refractory mutation system (ARMS) primers to selectively initiate amplification of the mutated genotype4; COLD-PCR and ICE-COLD-PCR that promote amplification of the mutant amplicon over the wild type amplicon by favoring the preferential denaturation of mutant targets6; and addition of allele-specific clamps, comprised of PNA15–17, LNA20, or linear oligonucleotides15, to preferentially inhibit primer extension on wild type targets.

This paper describes a new approach involving kinetic hybridization of a hairpin blocker to selectively amplify mutant targets during Linear-After-The-Exponential (LATE)-PCR. LATE-PCR is an advanced form of non-symmetric PCR in which specially designed primers in limiting and excess concentrations (“limiting primer” and “excess primer”, respectively) are used to amplify double-stranded DNA exponentially followed by linear amplification of single-stranded DNA. To achieve preferential amplification of mutant targets, the loop sequence of the hairpin blocker was designed to be fully complementary to the wild-type allele at the site of the mutation and partly complementary to the 3’ end of the upstream limiting primer. By manipulating the time allowed for hybridization of the blocker at certain temperatures during PCR, the blocker preferentially hinders binding of the limiting primer to wild-type targets thereby enabling selective amplification of mutant strands. Such selective inhibition is hereafter referred to as kinetic blocking. The concept of kinetic blocking was derived from the hybridization properties of hairpin-shaped oligonucleotides21. Hybridization of such structured oligonucleotides...
to their targets depends on both opening of the stem of the hairpin and hybridization of the loop to its complementary target sequence. Compared to other methods of selective amplification, kinetic hairpin blockers are inexpensive and flexible to use, i.e., they selectively interfere with amplification of their chosen target sequence depending on how they are used.

The single greatest limitation of all strategies for selective sequence amplification is the occurrence of false positives due to Taq polymerase errors. One way to decrease these errors is to use a high fidelity polymerase, such as Pfu. In the work reported here the problem of Taq DNA polymerase errors was minimized using a mismatched excess primer plus a modified LATE-PCR thermal profile, which together further promote selective amplification of the mutant type. In this system amplification of a rare mutant allele is at least 10,000 times more likely than amplification of a wild type allele in the absence of false positive signals.

Results

The Logic of Hairpin Blockers in LATE-PCR. Hairpin blockers are oligonucleotides with a stem-loop structure. The sequence of the loop is perfectly complementary to the wild type allele. The 3’ end of the blocker is capped to prevent extension and several nucleotides at the 5’ end of the blocker compete for target binding with the 3’ end of the upstream limiting primer. The Tm of the blocker to its fully complementary target sequence is about 10 – 12°C higher than the Tm of the blocker to the mutant target, and 15 – 17°C higher than the Tm of the upstream limiting primer to both targets. Under these conditions, the blocker preferentially hybridizes onto the wild type template strand and fails to bind the mutant template when the temperature of the reaction is paused at an optimal blocker binding temperature between the denaturation step and limiting primer annealing temperature, Figure 1. The extent of blocker binding to the wild-type target at this step is governed by the time it takes for the stem of the blocker to open. As a result, blocker efficacy can be optimized by simply adjusting the length of the blocker binding step. When the temperature is then lowered to enable annealing of the limiting and excess primers, the bound blocker prevents binding and extension of the limiting primer on the wild-type target molecules. But, at this lower temperature the blocker is less allele discriminating and can begin to bind to mutant target sequences if the stem is open. To reduce this possibility the temperature is lowered quickly from the blocker binding temperature to the limiting primer binding temperature. Rapid cooling and a lower temperature make the stem more difficult to open resulting in preferential binding and extension of the limiting primer to the mutant strand instead of the blocker. These adjustments in the timing of the thermal cycle result in preferential amplification of the mutant target. In contrast, if no blocker binding step is included in the thermal cycle and the temperature is lowered quickly, the limiting primer hybridizes to, and extends on both the wild type and the mutant templates, Figure 1. Thus, the ability of the blockers to interfere with amplification of their chosen target sequence is determined by how the blockers are used.

Adjusting the Kinetics of Hairpin Blocker by Changing the Length of the Stem. Hairpin oligonucleotides are more allele discriminating than linear probes because closure of the stem provides an alternative thermodynamically stable state of the hairpin molecule. As a result hairpin oligonucleotides exhibit a large Tm difference, 7–10°C, for hybridization to a perfectly matched versus a mis-matched target. In the present study we used dual labeled hairpin oligonucleotides (i.e., molecular beacons) to explore the hybridization kinetics of hairpin blockers to their targets. Six blockers B1, B5, B6, B7, B8 and B9 were constructed having the same loop sequence, except for B9 which has a 9 base pair stem and which appears to have a larger Tm. This blocker may have bound to the mutant sequence too slowly to give accurate Tm data.

| Table 1 | Equilibrium and kinetic binding of blockers with different stem length on wild type target or mutant type target |
|-----------------|-----------------------------------------------|
| Blocker (stem length) | Tm (wild type target) (°C) | Tm (mutant type target) (°C) | ΔTm | Maximum percentage to WT | Maximum percentage to MT | Time for fully binding (seconds) |
| B1 (1 bp) | 72 | 61 | 11 | 100 | 80 | 20 |
| B5 (5 bp) | 67 | 57 | 10 | 100 | 18 | 120 |
| B6 (6 bp) | 64 | 54 | 10 | 80 | 0 | 300 |
| B7 (7 bp) | 62 | 52 | 10 | 60 | 0 | >300 |
| B8 (8 bp) | 61 | 49 | 12 | 55 | 0 | >300 |
| B9 (9 bp) | 52 | 38 | 14 | 10 | 0 | >300 |
Table 1 also shows that the kinetics of blockers binding to the targets slows down with longer stems, from 20 seconds to more than 5 minutes. Blocker B5 was chosen for further use because it bound to 100% of wild type targets but only 18% of mutant targets during the blocking binding step, 60°C. The amount of time required for complete binding of B5 to the wild type target, 2 minutes, was also reasonable in practice.

**Effectiveness of a Hairpin Blocker in Rare Mutation Detection in Plasmid DNA.** Hairpin blocker B5 was first tested using two plasmid DNA targets containing the wild type KRAS gene or a variant of codon 12, a GGT→GAT mutation. The two plasmids were also engineered to have an additional SNP site downstream from the binding region of the blocker and the limiting primer for convenient identification of the amplification products using a mismatch-tolerant probe against the SNP site. Three LATE-PCR thermal cycle profiles were tested to establish the best conditions for blocking during amplification. In each case the kinetics of double-stranded DNA accumulation in real-time were analyzed using SYBR Green fluorescence at 72°C. The results in Figure 2 show that inclusion of the hairpin blocker, even in the absence of an extended blocker binding step, is sufficient to slow down amplification of 10,000 copies of the wild type sequence to the point that it had a Cq (quantification cycle) value equivalent to 1,000 copies of the mutant sequence. Inclusion of a 1-minute blocker binding step significantly increased the effect of the blocker on wild type target (seen as an increased Cq value) and also slightly improved the efficiency of mutant target amplification (seen as decreased Cq value). Inclusion of a 2-minute blocker binding step result in distinctly more inhibition of wild type target amplification plus a small additional improvement in the efficiency of mutant sequence and amplification. Quantification of these results shows that the thermal cycling protocol with a 1-minute blocker binding step reduces the amplification efficiency of wild type templates 100 fold relative to mutant target molecules, while a 2-minute blocker binding step favors mutant target amplification 200–1,000 fold over the wild type target.

**How Effective are Hairpin Blockers Really?** The results presented in Figures 2 raise a fundamental question. Is the selectivity of the kinetic blocker for the wild type sequence only 200–1,000 fold because the blocker fails to bind some wild type target molecules, or, is it only 200–1,000 fold because some wild type target molecules mutate within the blocker binding site due to Taq DNA polymerase errors and thereby escape blocker binding in subsequent rounds of exponential amplification? Taq DNA polymerase is known to make errors at a rate of about $2 \times 10^{-5} \sim 1 \times 10^{-4}$ per nucleotide.

To answer this question, we first examined the sequence of the downstream SNP by probing it with a mismatch-tolerant probe, LTPrb. This probe was fully complementary to the wild type sequence with a melting Tm of 55°C. It was partially mismatched to the mutant sequence and therefore had a melting Tm of 43°C. For this test 10 copies of the mutant plasmid were mixed with 10 or 100,000 copies of the wild type. The thermal cycle included a 2-minute/60°C blocker binding step for 55 cycles, as described above. The results show that the hairpin blocker selectively inhibited the wild type target when it was mixed 1:1 with the mutant target, but it failed to inhibit synthesis of the wild type target when it was present at a 10,000 fold excess over the mutant target, Figure 3A. This result appears to favor the possibility that the blocker simply fails to bind to all copies of the wild type plasmid DNA when they are present in excess over the mutant plasmid. However, an analysis of the blocker binding sequence itself demonstrates that this conclusion is wrong.

Figure 3B shows the melting temperature profiles of blocker B5 bound to the single stranded products of LATE-PCR amplification in the presence and absence of a 2-minute blocker binding step. In the absence of a blocker binding step during amplification, which we have demonstrated having a low blocking efficiency, the blocker binds the wild type product strands at the end of amplification with a Tm of 68°C. In contrast, inclusion of a blocker binding during amplification results in blocker binding to amplified product strands with a Tm less than 60°C, coincident with the peak of blocker binding to the mutant template. In other words, at least some of the wild type sequences appear to have accumulated mutations in the region of blocker binding.

To confirm this conclusion we sequenced single-stranded products of sixteen replicate reactions arising from pure 10,000 copies of wild type target amplified in the presence of the blocker and a 2-minute blocker binding step. As shown in Table 2, in every case the
sequence of the blocker binding region contained a mutation which significantly lowered the \( T_m \) of blocker target binding. Most of the sequence changes were G to A transitions, characteristic of Taq DNA polymerase errors. The KRAS mutations would strongly influence the kinetic hairpin blocker performance because they are far enough away from the third position of the modified TTT motif, which makes them able to bind with reasonable affinity. Because the block is done with excess primer and extension, the mis-matched limiting primer does not bind to either template.

The results presented above suggest that kinetic hairpin blockers would actually inhibit wild type target amplification more than 200–1,000 fold, were it not for Taq DNA polymerase errors. Use of a high fidelity enzyme would address this problem, but this approach would necessitate re-optimization of all the blocker and primer binding conditions described above to adjust to the buffer reaction conditions for the high fidelity enzyme. We turned instead to another strategy, selective linear pre-amplification. This strategy takes advantage of the fact that (i) preferential blocking of limiting primer hybridization and extension by the kinetic blocker on the original wild-type target strand is not affected by Taq DNA polymerase errors, and (ii) the \( T_m \) of the LATE-PCR limiting primer is higher than the \( T_m \) of the excess primer. Thus, it should be possible to selectively hybridize and extend the limiting primer on the mutant strand multiple times using a three-temperature cycling profile for denaturing, blocker binding, and limiting primer annealing as long as the temperature never drops to the point where the excess primer can hybridize and generate amplified target strands that could have Taq DNA polymerase errors. To enhance the \( T_m \) difference between the limiting and excess primer we replaced the standard excess primer with one that was deliberately mis-matched to its target sequences at its 3’ end. This strategy is schematically shown in Figure 4. We also modified the thermal cycle so that the reaction started with several cycles of linear amplification using only the limiting primer.

Figure 5 shows that the modified thermal cycle is divided into 8 segments. In Segment 1 the hotstart antibody is denatured and the Taq polymerase is activated. None of the oligos is bound to a template. In Segment 2 the temperature is lowered to selectively bind the blocker to the wild type template and then is lowered again to permit binding and extension of the limiting primer on the mutant template. The mis-matched excess primer does not bind to either template. Thus, only the mutant limiting primer strand is amplified and, because it does not bind the blocker there is no selection of any additional mutation within the blocker binding target sequence. In theory it is possible to repeat Segment 2 as many times as desired. In practice ten cycles seems a good number as it linearly amplified the mutant type by an order of magnitude within a reasonable time. In Segment 3 all of the oligonucleotides and new template strands are once again melted apart. In Segment 4 the temperature is lowered to selectively bind the wild type template strands and is then lowered again to a temperature sufficient for the mis-matched excess primer to bind to the new mutant limiting primer strands. Segment 4 is repeated four additional times by rapidly oscillating the temperature between 40 and 60 in order to guarantee that all single strands are converted to double strands. Segment 5 is an extension step at 72°C that guarantees that double-strands are full length. Segment 6 is comprised of 50 cycles of amplification at temperatures which block amplification of wild type templates and complete the switch from the exponential phase of LATE-PCR to the linear phase of single-strand production. Linear amplification is followed by analysis of product strand using low temperature Lights-On/Lights-Off probes as described below. Accordingly, Segment 7 is a step at 30°C to permit binding of probe and Segment 8 is an incremental probe/target melt with acquisition of fluorescent signals over the entire temperature range 30°C–85°C.

**Strategies for Overcoming the Problem of Taq Polymerase Errors.**

In order to get more detailed information and better discrimination of mutant and wild type signals we used Lights-On/Lights-Off probes. A Lights-On probe is dual labeled with a fluorophore and a quencher. A Light-Off probe, in contrast, is labeled with only a quencher moiety. When both probes are bound to a target, the Lights-Off probe serves to absorb energy from the fluorophore of its adjacent Lights-On probe. To implement this...
strategy, we placed a quencher on the blocker to convert it into a Lights-Off probe and designed a Lights-On probe that bound next to it. The T_m of the Lights-On probe was such that if the target is wild type the blocker/Lights-Off probe would bind on the target at a higher temperature than the Lights-On probe, resulting in no net fluorescence increase (i.e., the fluorescence signals from a wild-type target would therefore resemble those from a no template control). On the other hand, if the target is mutant-type, the blocker/Lights-Off probe would bind on the target at a temperature lower than the T_m of the Light-On probe. As the temperature in the reaction went down, the Lights-On probe would generate a signal and then be turned off as the adjacent Lights-Off probe binds at a lower temperature (Figure 6A). In a negative first derivative plot of fluorescence vs. temperature (-dF/dT), the Lights-On probe signal corresponds to a peak whereas the Lights-Off probe corresponds to a valley. In such a plot, a Lights-On probe fluorescent peak would indicate the presence of a mutant target. The lowest temperature of the Lights-Off probe fluorescent valley, which corresponds to the T_m of the Lights-Off blocker bound to a specific mutation, would identify individual mutations. As mentioned above, the wild type target would have the same fluorescent signatures as no template control samples (Figure 6B).

Figure 6C shows proof-of-principle evidence for selective rare mutation detection from the background of wild type using the combination of blocker, mismatched excess primer, modified LATE-PCR thermal profile and Lights-On/Lights-Off probes. As shown, under these conditions no mutant strands of any sort were detected when amplification was initiated using only 10,000 copies of the wild type plasmid, but addition of even a single copy of the mutant plasmid containing the GAT mutant codon resulted in amplification of single strands, a Lights-On signal peak, and a Lights-Off valley with a T_m of the blocker can then be optimized by adjusting the length and temperature of this special step. If no blocker binding step is included the T_m difference between wild type and mutant type and preferentially melt the mutant type target during PCR to enrich the amplification of mutant type. All the unknown mutations in the mutant target would be revealed after sequencing of mutant amplification products. However, the sensitivity is relatively low (down to only 1%). One of the most widely used approaches with more sensitivity uses allele-specific primers which are perfectly matched to a specific mutant target and mismatched to all other alleles to enhance a particular mutant type. The detection sensitivity reaches as low as 0.1%. However, once incorporated due to mis-amplification of a wild-type target, those primers turn all amplicons derived from wild type sequences into mutant amplicons. So any wild type target that escapes selection cannot be distinguished from a bona fide mutant. PNA and LNA clamps PCR keep the sequence of the targets but the manufacturing of PNA or LNA are very expensive. Furthermore, all the current PCR-based enrichment methods face the same biological problem which is difficult to overcome: generation of false-positive mutants due to DNA polymerase errors during amplification. For a certain rare mutation detection method to be used as a routine diagnostic tool, it must achieve a balance of high selectivity while maintaining the specificity, accuracy, convenience, and low cost.

Linear oligonucleotide DNA has been an inexpensive material for competing with the primers for binding on the target. We have reported using a linear blocker to sequence all DNA strands generated in multiplex LATE-PCR assays. In that study, a linear blocker was added to prevent all but one of the remaining excess primers in LATE-PCR product serving as the sequencing primer. We observed that when there is a secondary structure in the linear blocker, the blocking efficiency is dramatically decreased in the fast sequencing process. In the present report we took advantage of the slow binding kinetics of the hairpin structured oligonucleotide DNA and used it as a blocker for rare mutation detection.

In order to use the blocker for selective inhibition of the wild type target with no effect on the mutant type amplification it is necessary to introduce a blocker binding step in the thermal cycle. The efficacy of the blocker can then be optimized by adjusting the length and temperature of this special step. If no blocker binding step is included in the thermal cycle and the temperature is lowered quickly, blocker binding fails because the stem of the blocker does not have enough time to open. The limiting primer hybridizes to, and extends on both the wild type and the mutant templates. This feature of kinetic hair-

Table 2 | T_m of the blocker binding on targets with different mutated nucleotide. The target sequences were of the samples amplified from 10,000 wild type target with the blocker binding step of 2 minutes

| Kinetic Blocker Target Sequences | T_m (°C) |
|----------------------------------|---------|
| G G A G C T G G T G G C G T A G G C | 68.2    |
| T T A A A A A A A A A T T A A A A A | 56.7    |
| T T A A A A A A A A T T A A A A A | 56.7    |
| T T A A A A A A A A T T A A A A A | 56.7    |
| T T A A A A A A A A T T A A A A A | 56.7    |

*Calculated T_m.
pin blockers distinguishes them from linear blockers and blockers comprised of LNA or PNA. This feature also makes it possible to establish whether samples that fail to generate a fluorescent signal actually contain only wild type DNA rather than no DNA. All that is required in this case is to skip the blocker binding step and see if a signal is present.

Unlike strategies that depend on the use of mutation-specific ARMS-PCR primers the blocker strategy preserves, rather than erases, the mutation used for selective amplification. This is because the sequence of the limiting primer strand, created by extension of the limiting primer on the mutant target, retains the mutated base pair, making it possible to distinguish the products of amplification using a fluorescent labeled probe. In the PNA or LNA assays, the mutated nucleotide is also preserved. But these chemically special clamps are expensive and need to be removed in order to sequence or even probe the resulting amplicons.

Amplification of false-positives due to Taq DNA polymerase errors is the single greatest limitation of all strategies that depend on multiple rounds of selection and amplification. These errors actually arise by extension of the reverse primer, or the excess primer in the case of LATE-PCR. In order to circumvent this we deliberately used a mismatched excess primer, thereby reducing its $T_m$ during the first ten rounds of amplification, and we avoided use of this primer by carrying out ten initial cycles at an annealing temperature for limiting primer-only extension. This solution to the problem takes advantage of the fact that the limiting primer $T_m$ is higher than that of the excess primer $T_m$. The sensitivity of the assay is thus increased about 10 fold.

In addition to various methods of selective sequence amplification, droplet digital PCR has become another method of choice for detection of rare mutation32. Several studies have reported detection of KRAS mutations using this approach in which each droplet contains either a single DNA molecule or no DNA33,34. The detection sensitivity reaches 0.01% ~ 0.001% for certain alleles. The hairpin blocker method can readily be combined with droplet PCR to further improve detection sensitivity. In addition, the combined approach is very attractive because it makes it feasible to dilute the sample to single copy of DNA in each droplet unnecessary, thus eliminating the need for having “wasted” droplets that contain no DNA. For instance, if 1000 copies of wild type DNA were present in each droplet, no droplet would generate a signal. In contrast, if 1% of droplets signaled, the frequency of the mutant would be 0.001% (the current detection limit of droplet PCR) and if 0.1% of droplets signaled (i.e., 1 droplet in 1000), the frequency of the mutant would be 0.0001% (1/1000). Even lower frequencies of mutant alleles could be detected by rapidly screening several thousands of droplets at a time, as is currently done33, thereby making detection sensitivity virtually unlimited. Finally, the combined approach would make it easy to construct multiplexed reactions for analysis of several gene targets at the same time in the same droplets.

**Methods**

*Oligonucleotides used in the experiments.* Limiting Primer, LP: 5’ACTCTTGCC-TAGGC 3’ ($T_m$=52°C at 50 nM)

Excess Primer, XP: 5’GGCTGATTGGATATAG 3’ ($T_m$=51°C at 1000 nM)

Mismatched Excess Primer: 5’GGCTGATTGGATATAG (Tm=45°C, when matched to the target, and $T_m$=51°C, when matched to the target at 1000 nM)

Wild-type synthetic target: 5’GTAGTGGACTGCTTTGGCGTACGCAAGT 3’

Mutant-type synthetic target: 5’GTAGTGGGAGCTGCTTTGGCGTACGCAAGT 3’

Blocker B1: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B2: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B3: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B4: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B5: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B6: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B7: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B8: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B9: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B10: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B11: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B12: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B13: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B14: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B15: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B16: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B17: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B18: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B19: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B20: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B21: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B22: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B23: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B24: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B25: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B26: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B27: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B28: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B29: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B30: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B31: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B32: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B33: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B34: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B35: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B36: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B37: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B38: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B39: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

Blocker B40: 5’ Cal Org 560-GCGGTACCGGCCAGCTCC-Dabcyl 3’

All of the primers, probes and blockers were ordered from BioPhen Bioscience (CA, USA). The probes and blockers were purified by dual HPLC and the primers were salt-free purified. The binding sites of the blockers and probes to the targets are underlined. The nucleotides that form the stem of a blocker or a probe are bolded. The mutation position in the synthetic targets above is squared.
Target DNA used in the experiments. Plasmid DNAs were used as the targets in this work as a proof-of-principle investigation. The plasmids containing the interesting part of KRAS gene with wild type and mutant type alleles in codon 12 were ordered from Epoch Biolabs Inc. (Sugar Land, TX). An additional artificial single nucleotide polymorphism (SNP) was intentionally included in the mutant target sequence as shown below.

Wild type target excess primer strand is

$$\text{5'CTGGTGGAGTATTTGATAGTGTATTAAC...3'}$$

Mutant type target excess primer strand is

$$\text{5'CTGGTGGAGTATTTGATAGTGTATTAAC...3'}$$

The blocker binding site is bold underlined and the GGT->GAT mutation in KRAS codon 12 is boxed in. The downstream probe binding site is double underlined and the artificial SNP site within it is shown as a larger bolded letter in the sequence.

Blocker Thermodynamic and Kinetic Investigation. 100 nM each blocker with different stem lengths from 1 bp stem to 9 bp stems (B1, B5, B6, B7, B8, B9) was mixed with 250 nM wild type target or mutant type target to obtain its thermodynamic equilibrium $T_m$. The solutions were kept at 30°C for 10 minutes to allow complete formation of probe-target hybrids. Then a melt starting at 30°C with 1°C increments at 30 s intervals to 90°C was monitored. The peak position of the negative first derivative of the melting fluorescence gave the $T_m$ of each blocker. In experiments investigating the kinetics blockers with different stem lengths to wild type or mutant type targets, 100 nM of each blocker was mixed with 250 nM wild type or mutant type target, or no target, established background fluorescence at a certain temperature. The mixtures were then heated to 95°C for 30 seconds to melt.

Figure 5 | PCR profiles for employing mismatched excess primer for selectively amplifying mutant type targets.

Figure 6 | (A) Schematics of the temperature-dependent hybridization of a set of Lights-On/Lights-Off probes to wild type and mutant type targets, where Lights-Off probe has a higher $T_m$ than the Lights-On probe, and (B) their resulting fluorescent signature (the negative first derivative of fluorescence melting curve); red line, wild-type targets; green line, mutant targets; dotted black line, no template control. (C) Fluorescent signatures of 10,000 copies of pure wild type or a mixture of 10,000 copies of wild type targets with different concentration of mutant type targets. Here On68 and Off62 are consisted in the Lights-On/Lights-Off probe set and Off62 also works as a blocker. (D) Sanger sequencing results for the sample in (C) with single mutant type and 10,000 wild type targets.
the double strands, then were cooled to 60 °C and held there for 5 minutes. Fluorescence reading was taken every 5 seconds at 60 °C to monitor how much probe was bound to targets with time. All samples were run in duplicate.

All experiments were carried out in a Stratagene MX3000P PCR machine.

**PCR Reaction mixtures.** LATE-PCR amplifications were performed using 25 μl reaction mixtures containing 1× PCR buffer (Invitrogen, Carlsbad, CA), 3 mM MgCl2, 200 nM dNTPs, 0.24× SYBR Green (Invitrogen, Carlsbad, CA), 50 nM limiting primer LP, 1000 nM excess primer XP/mMXP, 500 nM blocker BS/OIf62, 100 nM molecular beacon probes LT/prb/On68. 1 unit of Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA), and different concentrations of DNA target variants in the range of 1 to 10,000 copies, as determined by serial dilutions. Amplification reactions were run in duplicates.

**PCR Profiles.** Two excess primers were used in this work, perfectly matched (XP) or mismatched (mMXP). The LATE-PCR profiles used with the perfectly matched excess primer (XP) were as follows: 95 °C for 3 min followed by 55 cycles of 95 °C/10 sec, 60 °C/2 min, 50 °C/10 sec, 72 °C/20 sec, followed by a 10 min pause at 30 °C then a melt starting at 30 °C with 1 C increments at 30 sec intervals to 90 °C. SYBR signals were monitored during amplification and Quasar 670 signals from the molecular beacon probe were detected during the melting process.

When mMXP was used, the LATE-PCR profiles were as follows: 95 °C for 3 min; 10 cycles of 95 °C/10 sec, 60 °C/2 min, 50 °C/10 sec, 72 °C/20 sec; 1 cycle of 95 °C/10 sec; 1 cycle of 60 °C/2 min and 40 °C/30 sec with 4 cycles of quick cycling between 60 °C and 40 °C; 1 cycle of 72 °C/2 min; 50 cycles of 95 °C/10 sec, 60 °C/2 min, 50 °C/10 sec, 72 °C/30 sec (with SYBR signal reading); followed by a 10 min pause at 30 °C, then a melt starting at 30 °C with 1 C increments at 30 sec intervals to 90 °C. Quasar 670 signals from the Lights-On/Lights-Off probe sets were detected during the melting process.

1. Garassino, M. C. et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. *Ann Oncol.* 22, 235–237 (2011).
2. Taylor, R. W. & Turnbull, D. M. Mitochondrial DNA mutations in human disease. *Nat Rev Genet.* 6, 389–402 (2005).
3. Lin, E. H. et al. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). *J Thorac Oncol.* 4, 12–21 (2009).
4. Parsons, B. L. & Meng, F. K-RAS mutations in the screening, prognosis and treatment of cancer. *Biomat Med.* 3, 757–769 (2009).
5. Riel, G. J., Marks, J. & Pao, W. KRAS mutations in non-small cell lung cancer. *Proc Am Thorac Soc.* 6, 201–205 (2009).
6. Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Med.* 2, e17 (2005).
7. Heinrich, M. C. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. *J Clin Oncol.* 21, 4342–4349 (2003).
8. Di Fiore, F. et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. *Br J Cancer.* 96, 1166–1169 (2007).
9. Allegra, C. J. et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. *J Clin Oncol.* 27, 2091–2096 (2009).
10. Engstom, P. F. et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. *J Natl Compr Canc Netw.* 7, 778–831 (2009).
11. Silva, J. M. et al. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. *Clin Cancer Res.* 8, 3761–3766 (2002).
12. Sorenson, G. D. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. *Clin Cancer Res.* 6, 2129–2137 (2000).
13. Milbury, C. A., Li, J. & Markirigors, G. M. PCR-based methods for the enrichment of minority alleles and mutations. *Clin Chem.* 55, 632–640 (2009).
14. Newton, C. R. et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). *Nucleic Acids Res.* 17, 2503–2516 (1989).
15. Li, J. et al. Replacing PCR with 2COLD PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. *Nature Medicine* 14, 579–584 (2008).
16. Chiou, C. C., Luo, J. D. & Chen, T. L. Single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe for the detection of rare mutations. *Nat Protoc.* 1, 2604–2612 (2006).
17. Thiede, C. et al. Blockers for Selective Amplification of Rare Mutations. *Natl Acad Sci U S A* 96, 6171–6176 (1999).
18. Jacobs, G. et al. Enrichment polymerase chain reaction for the detection of K-ras mutations: relevance of Taq polymerase error rate, initial DNA copy number, and reaction conditions on the emergence of false-positive mutant bands. *J Cancer Res Clin Oncol.* 125, 395–401 (1999).
19. Gilje, B., Heikkilä, R., Oititalo, S., Tjensvoll, K. & Nordgård, O. High-Fidelity DNA Polymerase Enhances the Sensitivity of a Peptide Nucleic Acid Clamp PCR Assay for K-ras Mutations. *J Mol Diagn.* 10, 325–331 (2008).
20. Tyagi, S., Bratu, D. P. & Kramer, F. R. Multicolor molecular beacons for allele discrimination. *Nat Biotechnol.* 16, 49–53 (1998).
21. Marras, S. A., Kramer, F. R. & Tyagi, S. Multiplex detection of single-nucleotide variations using molecular beacons. *Genet Anal.* 14, 151–156 (1999).
22. Bos, J. L. Ras oncogenes in human cancer: a review. *Cancer Res.* 49, 4682–4689 (1989).
23. Bustin, S. A. et al. The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments. *Clinical Chemistry* 55, 611–622 (2009).
24. Tindall, K. R. & Kunkel, T. A. Fidelity of DNA synthesis by the Thermus aquaticus DNA polymerase. *Biochemistry.* 27, 6008–6013 (1988).
25. Overbaugh, J., Jackson, S. M., Papenhausen, M. D. & Rudensky, L. M. Lentiviral Genomes with G-to-A Hypermutation May Result From Taq Polymerase Errors during Polymerase Chain Reaction. *AIDS Research and Human Retroviruses* 12, 1695–1613 (1996).
26. Rice, J. E., Reis, A. H. J., Rice, L. M., Carver-Brown, R. K. & Wangh, L. J. Fluorescent signatures for variable DNA sequences. *Nucleic Acids Res.* 40, e164 (2012).
27. Jia, Y., Osborne, A., Rice, J. E. & Wangh, L. J. Dilute-'N'-Go dideoxy sequencing of all DNA strands generated in multiplex LATE-PCR assays. *Nucleic Acids Res.* 38, e119 (2010).
28. Hindson, B. J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. *Anal Chem.* 83, 8604–8610 (2011).
29. Pekin, D. et al. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. *Lab Chip* 11, 2156 (2011).
30. Azzara, D. et al. Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer. *Clinical Chemistry* 58, 1332–1341 (2012).

**Acknowledgments**

This work was supported by a research grant to L.J.W. from Smith Detection Diagnostics, Inc.

**Author contributions**

The project was designed by L.J.W., Y.W.J. and J.A.S. Experiments were run and analyzed by Y.W.J. The paper was written by Y.W.J., L.J.W. and J.A.S.

**Additional information**

**Competing financial interests:** The authors declare no competing financial interests.

How to cite this article: Jia, Y., Sanchez, J.A. & Wangh, L.J. Kinetic Hairpin Oligonucleotide blockers for Selective Amplification of Rare Mutations. *Sci. Rep.* 4, 5921; DOI:10.1038/srep05921 (2014).